Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 16, 2020, Kaleido Biosciences, Inc. (the "Company") announced that Alison Lawton has resigned as the Company's President and Chief Executive Officer ("CEO") effective June 16, 2020 to return to the United Kingdom and attend to an unexpected family health matter. Ms. Lawton informed the Board of Directors of her decision on June 14, 2020. Ms. Lawton will continue to serve as a Director and special advisory to the Company and will support the Company through this transition. The Company is working on an Employment and Separation Agreement with Ms. Lawton to set forth her agreed upon post-resignation compensation and responsibilities.

The Company's Board of Directors (the "Board") will be initiating a search for a new CEO and has established an Office of the CEO to lead the organization and to advance its strategic goals during this transition period. The Office of the CEO will be comprised of Mike Bonney, the Company's Executive Chair and former CEO, and Ms. Lawton. Other members of the Board of Directors have also committed to providing their expertise and support to the organization until a successor CEO is identified.

The Company issued a press release on June 16, 2020 announcing Ms. Lawton's resignation and formation of the Office of the CEO. A copy of the press release is being furnished as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits:



Exhibit No.   Description

99.1            Press Release issued by the Company on June 16, 2020, furnished hereto.
104           Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses